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ORIGINAL ARTICLE
Combined adverse effects of maternal smoking and
high body mass index on heart development in
offspring: evidence for interaction?
Maria E Baardman,1 Wilhelmina S Kerstjens-Frederikse,2 Eva Corpeleijn,3
Hermien E K de Walle,1 Robert M W Hofstra,2 Rolf M F Berger,4 Marian K Bakker1
ABSTRACT
Objective To study the influence of a possible interaction
between maternal smoking and high body mass index
(BMI) on the occurrence of specific congenital heart
anomalies (CHA) in offspring.
Design Case-control study.
Setting Data from a population-based birth defects
registry in the Netherlands.
Patients Cases were 797 children and fetuses born
between 1997 and 2008 with isolated non-syndromic
CHA. They were classified into five cardiac subgroups:
septal defects (n¼349), right ventricular outflow tract
obstructive anomalies (n¼126), left ventricular outflow
tract obstructive anomalies (n¼139), conotruncal
defects (n¼115) and other CHA (n¼68). Controls were
322 children and fetuses with chromosomal anomalies
without cardiac anomalies.
Main outcome measures Investigation of whether an
interaction between maternal smoking and high BMI
influences the occurrence of CHA in offspring by
calculation of the synergy factors and 95% CIs.
Results As opposed to smoking or high BMI alone, the
risk for CHA in the offspring of women with high BMI
($25 kg/m2) who also smoked was significantly
increased. The adjusted OR was 2.65 (95% CI 1.20 to
5.87) for all CHA, 2.60 (95% CI 1.05 to 6.47) for septal
defects and 3.58 (95% CI 1.46 to 8.79) for outflow tract
anomalies. The interaction between maternal high BMI
and smoking contributed significantly to the occurrence
of all offspring-CHA combined, and to the occurrence of
all cardiac subgroup anomalies except right ventricular
outflow tract obstructive anomalies.
Conclusions Maternal overweight and smoking may
have a synergistic adverse effect on the development of
the fetal heart. Overweight women who wish to become
pregnant should be strongly encouraged to stop smoking
and to lose weight.
INTRODUCTION
Congenital heart anomalies (CHA) are among the
most common congenital anomalies with a preva-
lence of approximately 8 per 1000 births.1 Little is
known about the aetiology of CHA and a plausible
cause is found in only 15% of cases2; both genetic
and exogenous factors may play a role. Exogenous
factors that have been associated with an increased
risk of CHA include maternal conditions such as
phenylketonuria, diabetes, rubella infection and
epilepsy. The use of medication in pregnancy such
as thalidomide, vitamin A derivatives, antiepileptic
drugs, certain selective serotonin reuptake inhibi-
tors and indomethacin is also associated with
CHA.3 Lifestyle factors that have been associated
with CHA are smoking and alcohol consumption,
whereas the use of folic acid showed a protective
effect.3 4 A high maternal pre-pregnancy weight has
also been suggested as a risk factor for CHA in
offspring.5e8
Smoking rates among Dutch women of fertile
age are high with a prevalence of around 25%. More
than half of these women continue smoking during
pregnancy.9 The increasing prevalence of over-
weight and obesity has developed primarily over
the last decade. Over 30% of Dutch women aged
25e35 years are now overweight.10
Most causes of disease depend on the presence of
other factors to assert their effects. This is also
known as interaction. Smoking and overweight/
obesity are known to interact in the origin of
cardiovascular disease, particularly in arterioscle-
rosis; the combined effect of smoking and obesity
augments the risk for stroke, myocardial infarction
and sudden death.11 12 In parallel, we hypothesised
that this interaction between maternal high body
mass index (BMI) and smoking could also have
a substantial inﬂuence on the development of the
fetal heart.
The interaction between smoking and high
maternal BMI on the occurrence of speciﬁc CHA in
offspring has not been studied to date. CHAs are
complex diseases and both genetic factors and
exogenous factors play an important role.13
Important effects may be missed if risk factors are
independently examined. If the interaction
between risk factors such as maternal smoking and
high pre-pregnancy weight is elucidated, this will
result in better opportunities for prevention. We
therefore investigated whether there is an interac-
tion effect of maternal smoking and high BMI on
the risk of CHA using a case-control study design.
METHODS
We used data from Eurocat Northern Netherlands
(Eurocat NNL), a population-based birth defects
registry. The annual number of births covered is
approximately 19 000. Live births, stillbirths and
terminations of pregnancies for congenital anoma-
lies are included in the database if the mother lived
in the registration area at the time of birth and if
the child had not reached the age of 16 years at the
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time of notiﬁcation. Notiﬁcation of children and fetuses with
birth defects is voluntary. Registry staff are actively involved in
case ascertainment using multiple sources. Written informed
consent is obtained from the parents before registration. The
participation rate is approximately 80%. Information on char-
acteristics such as age, height, pre-pregnancy weight, chronic
illnesses, education and information on lifestyle factors (such as
smoking and alcohol consumption) are provided by the parents
through a questionnaire. The response rate on the questionnaire
is 80%.
Cases were deﬁned as children and fetuses with an isolated
non-syndromic CHA, which means that only the heart was
affected and the CHA was not accompanied by any other (non-
cardiac) congenital anomalies. Cases were born between 1997
and 2008 and included live births, stillbirths, miscarriages and
terminations of pregnancy because of congenital anomalies. All
children with a CHA in the registration area were seen by
a paediatrician or a paediatric cardiologist. Coding and classiﬁ-
cation of the CHA was based on the diagnostic information in
the medical ﬁles. Each case was classiﬁed into one of the
following subgroups according to a system based on current
developmental and epidemiological insights14: septal defects,
conotruncal defects, outﬂow tract anomalies and other heart
defects.
Because Eurocat NNL does not collect information on non-
malformed children, controls were deﬁned as children and
fetuses with a chromosomal anomaly not accompanied by
a CHA. The use of malformed controls from the same
geographical area and from the same birth years in case-control
studies on risk factors for birth defects is widely accepted.15 The
rationale for choosing chromosomal disorders is that the origin
of these disorders is not related to the risk factors being studied.
To minimise selection bias, we excluded all children and fetuses
with a chromosomal defect and CHA conﬁrmed by a prenatal or
postnatal echocardiogram, surgery or autopsy report. We also
excluded those without information from an echocardiogram
or from an autopsy report to ensure no controls with an
undetected structural heart defect were included.
BMI was calculated as pre-pregnancy weight (kg) divided by
squared height (m) and classiﬁed into the following WHO
categories16: underweight (BMI <18.5 kg/m2), normal weight
(BMI 18.5e24.9 kg/m2), overweight (BMI 25.0e29.9 kg/m2) and
obese (BMI $30.0 kg/m2). The categories overweight and
obesity were combined in a group of ‘high BMI’ (BMI $25.0 kg/
m2). We excluded underweight women because the numbers
were too small to perform meaningful analysis. Because low
BMI is reported as a risk factor for birth defects, we did not
include them in the reference group of normal BMI. Smoking
was deﬁned as ‘smoking before and during the ﬁrst trimester of
pregnancy (periconceptional)’, whereas no smoking was deﬁned
as ‘no smoking during the entire pregnancy period’. Women with
missing information on BMI or smoking, women who smoked
occasionally or <1 cigarette per day or only during the second
and third trimester were excluded from the analyses.
Potential confounders included maternal age, education level,
chronic illness (requiring regular medication use), folic acid use,
alcohol consumption and gestational diabetes. Three education
levels were distinguished: low (primary school, lower general
secondary education and lower vocational education), middle
(higher general secondary education and intermediate vocational
education) and high (university, further tertiary college and
higher vocational education). Folic acid use was classiﬁed into
two groups: correct use (400 or 500 mg per day started 4 weeks
before conception and taken until the eighth week of pregnancy)
and incorrect use (no use, use in wrong period or wrong dose:
<400 mg). Alcohol consumption was deﬁned as any alcohol
taken in the ﬁrst trimester of pregnancy; no alcohol was deﬁned
as no consumption in the ﬁrst trimester. Women who drank
alcohol occasionally or only during the second and third
trimesters were excluded from the analysis. We excluded
mothers with pregestational diabetes because maternal diabetes
is related to BMI and smoking and is associated with CHA.
Maternal characteristics were explored using the c2 test for
categorical variables and the ManneWhitney U test for
maternal age because the distribution of maternal age was
skewed in the control group. The risk for CHA was calculated
based on four exposure categories: normal weight and non-
smoking (reference category); high BMI and non-smoking;
normal weight and smoking; and high BMI and smoking. Crude
and adjusted ORs were calculated using logistic regression. SPSS
for Windows V.16.0 was used for the statistical analyses. A p
value of <0.05 and 95% CI excluding 1.0 was considered to be
statistically signiﬁcant.
Interaction was assessed using the synergy factors (SF) by the
method of Cortina-Borja.17 This model is based on departure
from multiplicativity. The SF is deﬁned as the ratio of the
observed OR for two dichotomous determinants (x and y)
combined to the predicted OR assuming independent effects of
each other: SF¼ ORxy/(ORx 3 ORy).18 For more information on
synergy factor analysis we recommend the open access supple-
mentary ﬁles in the paper by Cortina-Borja17 on the website
http://www.biomedcentral.com/1756-0500/2/105. We assumed
that smoking and BMI were neither sufﬁcient nor necessary for
the development of CHA, but interact on a more general
physiological pathway that affects the development of CHA.
In addition to these analyses, we explored the association
between smoking and BMI separately with the main cardiac
subgroups and with speciﬁc CHA to check the validity of our
data. Speciﬁc heart anomalies with <5 affected cases (smoking
or BMI subgroups) were not analysed separately but only
included in the main cardiac subgroup. Logistic regression was
used to determine the adjusted ORs (ORadj) and 95% CI.
RESULTS
On 1 October 2009 there were 6399 children and fetuses with
a congenital anomaly registered in the Eurocat database,
including 1462 with a malformation of the circulation system
(22.8%). In 1014 cases (69.4%) there was an isolated non-
syndromic CHA, of which 212 (20.9%) had a complex CHA and
802 (79.1%) had a single CHA. We identiﬁed 411 controls with
a non-cardiac chromosomal disorder. The majority of the
controls had a numeric chromosomal anomaly (trisomy 21 in
44%, trisomy 18 in 8%, Turner syndrome in 6%, triploidy in 4%,
trisomy 13 in 2%). The remaining 36% of the controls had
deletions of the autosomes, unbalanced translocations or other
chromosomal abnormalities and Mendelian-inherited disorders.
After excluding mothers with pregestational diabetes (7 cases, 3
controls), those who were underweight (28 cases, 9 controls)
and those with no information on smoking and BMI (182 cases,
77 controls), we identiﬁed 797 cases with a CHA and 322
controls with a non-cardiac chromosomal disorder. Table 1
shows the characteristics of these subjects.
As expected there was a difference in maternal age between
the cases and controls, since the prevalence of chromosomal
anomalies increases with higher maternal age. More miscar-
riages, stillbirths and terminations of pregnancies occurred
among the controls. There were no statistically signiﬁcant
differences between cases and control with respect to ﬁrst
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pregnancy, chronic illness, education level, folic acid use, alcohol
consumption or gestational diabetes.
In total, 281 case mothers (35.3%) and 94 control mothers
(29.2%) had a high BMI. Periconceptional smoking was recorded
for 199 case mothers (25.0%) and 61 control mothers (18.9%).
Table 2 shows the distribution of BMI and periconceptional
smoking among case and control mothers. It should be noted
that both smoking and obesity were recorded for 19 case
mothers in the periconceptional period, whereas none of the
obese mothers in the control group smoked in this period.
In table 3 the numbers, crude and adjusted ORs and 95% CI of
the four exposure groups are shown. We found no signiﬁcantly
increased ORs for all CHA and for the cardiac subgroups in the
exposure categories high BMI/no smoking and normal BMI/
smoking. In the combined exposure group high BMI/smoking
a signiﬁcantly increased OR was found for all CHA and for the
speciﬁc cardiac subgroups. The adjusted ORs were lower but still
statistically signiﬁcant for all cardiac subgroups except for
conotruncal defects. The highest adjusted OR was found for
right ventricular outﬂow tract obstructive anomalies (RVOTO).
In table 4 the SF and 95% CI are shown for the combined
exposure group high BMI/smoking. Except for RVOTO defects,
the SF was statistically signiﬁcant for all the subgroups.
With respect to the main effects of smoking and high BMI
(speciﬁed as overweight and obese) on the subgroups and speciﬁc
types of CHA, we found that RVOTO defects were signiﬁcantly
associated with high BMI. When taking the BMI categories
overweight and obesity into account, we found a signiﬁcant
association between RVOTO and overweight. Obesity was
signiﬁcantly associated with all CHA, septal defects, ventricular
septal defects (VSD) perimembraneous and VSD combined/not
otherwise speciﬁed. Smoking was signiﬁcantly associated with
atrial septal defects, secundum type (ASDII) and pulmonary
valve stenosis/atresia with ASDII and/or VSD (see appendix in
online supplement).
DISCUSSION
Our study has shown that smoking and high BMI strongly
interact in the risk of CHA in offspring. We found that the
combination of maternal smoking and high BMI increased the
risk for CHA in offspring more than would be expected from the
product of the individual effects of these two exposures.
Although the combined adjusted OR was the highest for
RVOTO defects (table 3), the interaction was not statistically
signiﬁcant for this cardiac subgroup (table 4). Lack of power
could be an explanation, since RVOTO is one of the smallest
subgroups in our study. The use of a multiplicative model to
calculate interaction could be another explanation. Other studies
have argued that a multiplicative model is often ‘too strong’ to
pick up signals of small joint effects of two biological risk factors
and therefore ‘biological interaction’ needs to be calculated on an
additive scale.17 19e21 Interaction effects with a more additive
character might not show an interaction on a multiplicative
scale when the combined OR is similar to the predicted OR
(SF ¼ ORxy/(ORx 3 ORy) eg, 15/(3 3 5)¼1). However, there is
still a lot of discussion on how additive interaction should be
calculated for case-control studies. Furthermore, it is unclear
how to interpret outcome measures of interaction calculated on
an additive scale. We therefore used a multiplicative model to
measure interaction.
The results of our study need to be interpreted in the light of
the complexity of the disease. Because the association between
environmental factors and CHA is probably strongest in children
with an isolated non-syndromic CHA, we carefully deﬁned the
inclusion criteria for the case group in order to create a homo-
geneous group without other (complicating) anomalies. In
addition, we deﬁned a range of cardiac subgroups to study






p Value*n (%) n (%)
Year of birth
1997e1998 141 (17.7) 68 (21.1) 0.33
1999e2000 147 (18.4) 66 (20.5)
2001e2002 152 (19.1) 74 (23.0)
2003e2004 147 (18.4) 45 (14.0)
2005e2006 137 (17.2) 41 (12.7)
2007e2008 73 (9.2) 28 (8.7)
Type of birth/death
Livebirth 699 (87.7) 232 (72.0) 0.00
Died after birth 80 (10.0) 20 (6.2)
Miscarriage 2 (0.3) 15 (4.7)
Termination of pregnancy 9 (1.1) 35 (10.9)
Stillbirth 7 (0.9) 20 (6.2)
Sex
Boys 421 (52.8) 174 (54.0) 0.71
Girls 376 (47.2) 148 (46.0)
Education level
Low 154 (19.4) 62 (19.4) 0.57
Middle 393 (49.6) 149 (46.6)
High 245 (31.0) 109 (34.0)
Unknown 5 2
Maternal age at delivery (years)
Median (25the75th percentile) 30 (27e34) 33 (29e36) 0.00
First pregnancy
No 515 (64.6) 224 (69.6) 0.11
Yes 282 (35.4) 98 (30.4)
Correct use of folic acid supplements
No use or wrong period 306 (49.7) 123 (46.9) 0.46
Yes 310 (50.3) 139 (53.1)
Unknown 181 60
Periconceptional alcohol consumption
No 599 (79.0) 239 (76.4) 0.17
Yes 159 (21.0) 74 (23.6)
Unknown or only after the first trimester 39 9
Maternal chronic illness
No 658 (85.5) 278 (87.7) 0.33
Yes 112 (14.5) 39 (12.3)
Unknown 27 5
Gestational diabetes
Yes 8 (1.0) 3 (0.9) 0.91
No 789 (99.0) 319 (99.1)
*c2 test.
Table 2 Distribution of combined maternal pre-pregnancy weight and
periconceptional smoking among informative cases and non-cardiac
chromosomal controls in the Eurocat database (1997e2008)
Cases (n[797) Controls (n[322)
Smoking Smoking
No Yes No Yes
Normal BMI 390 (49%) 126 (16%) 175 (54%) 53 (17%)
High BMI 208 (26%) 73 (9%) 86 (27%) 8 (2%)
Overweight 146 (18%) 54 (7%) 69 (21%) 8 (2%)
Obese 62 (8%) 19 (2%) 17 (5%) 0 (0%)
Normal body mass index (BMI) 18.5e24.9 kg/m2; high BMI $25.0 kg/m2; overweight
25.0e29.9 kg/m2; obese $30 kg/m2.
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speciﬁc associations. Because Eurocat NNL registers children up
to 16 years of age, CHA cases that were discovered later in
childhood were also included in the study whereas other studies
normally include only children diagnosed up to 1 year of age.
Our registry also contains information on genetic defects asso-
ciated with heart defects discovered later in childhood. We are
therefore able to identify isolated non-syndromic cardiac
malformations and to exclude heart defects with a known
genetic cause. However, it is possible that, with improved
techniques, a genetic cause will be found in the future in some
cases with an isolated non-syndromic CHA.
In the absence of non-malformed controls and because
smoking and BMI have been associated with different congenital
malformations, we included only children and fetuses with non-
cardiac chromosomal anomalies in the control group. Although
associations between maternal smoking and early fetal loss have
been described,22 causality between the risk factors being studied
and chromosomal anomalies has not been proven. Because we
cannot rule out the possibility that lifestyle factors and other
determinants differ between mothers of children with a chro-
mosomal disorder and mothers of non-malformed children,
the translation of the results to the general population of preg-
nant women should be regarded with caution. We encourage
other researchers to verify our results in their datasets using
non-malformed controls.
Data on maternal BMI and periconceptional smoking were
obtained retrospectively for both cases and controls through
a questionnaire ﬁlled in by the mother. The use of malformed
controls minimises the possibility of differential recall between
the cases and controls. It is likely that we have underestimated
the proportion of overweight and obese mothers because women
tend to report a lower weight than in reality. However, any
recall bias in this direction would most likely be non-differential
and result in an underestimation of the effect.
In our analyses we adjusted for potential confounding factors
such as educational level and alcohol consumption, which are
known to interfere with determinants and outcome variables in
other studies. We did not adjust for gestational diabetes (GDM)
for different reasons. First, GDM develops throughout the
second trimester of pregnancy when most of the heart struc-
tures have already developed. Second, blood glucose levels were
analysed in all the women in the ﬁrst trimester of pregnancy. In
addition, the results in table 3 were comparable when excluding
mothers with GDM.
Previous case-control studies on maternal smoking and high
BMI in relation to CHA risk in human offspring have found
Table 3 Crude and adjusted ORs (95% CI) for maternal smoking, high BMI and both factors combined
for different cardiac subgroups relative to non-cardiac chromosomal controls in the Eurocat database
(1997e2008)
Normal BMI High BMI (‡25 kg/m2) Normal BMI High BMI (‡25 kg/m2)
No smoking (n) No smoking (n) Smoking (n) Smoking (n)
Chromosomal controls (n¼322) 175 86 53 8
All CHA (n¼797)
N 390 208 126 73
OR (95% CI) ref 1.09 (0.80 to 1.48) 1.07 (0.64 to 1.54) 4.10 (1.93 to 8.68)
ORadj (95% CI)* ref 1.05 (0.72 to 1.54) 0.96 (0.61 to 1.05) 2.65 (1.20 to 5.87)
Septal defects (n¼349)
N 177 86 59 27
OR (95% CI) ref 0.99 (0.69 to 1.42) 1.10 (0.72 to 1.69) 3.34 (1.48 to 7.55)
ORadj (95% CI)* ref 0.95 (0.60 to 1.50) 1.00 (0.58 to 1.70) 2.60 (1.05 to 6.47)
Conotruncal defects (n¼115)
N 60 31 15 9
OR (95% CI) ref 1.05 (0.63 to 1.74) 0.83 (0.43 to 1.57) 3.28 (1.21 to 8.89)
ORadj (95% CI)* ref 1.00 (0.55 to 1.83) 0.67 (0.30 to 1.49) 2.86 (0.93 to 8.84)
Outflow tract anomalies (n¼265)
N 121 75 39 30
OR (95% CI) ref 1.26 (0.86 to 1.86) 1.06 (0.66 to 1.71) 5.42 (2.40 to 12.24)
ORadj (95% CI)* ref 1.35 (0.85 to 2.17) 0.90 (0.49 to 1.64) 3.58 (1.46 to 8.79)
Left ventricular outflow tract obstructive anomalies (n¼139)
N 66 38 20 15
OR (95% CI) ref 1.17 (0.73 to 1.89) 1.00 (0.56 to 1.80) 4.79 (2.01 to 12.27)
ORadj (95% CI)* ref 1.18 (0.67 to 2.10) 0.78 (0.37 to 1.67) 3.32 (1.12 to 9.80)
Right ventricular outflow tract obstructive anomalies (n¼126)
N 55 37 19 15
OR (95% CI) ref 1.37 (0.84 2.24) 1.14 (0.63 to 2.09) 5.97 (2.40 to 14.82)
ORadj (95% CI)* ref 1.57 (0.86 to 2.87) 1.02 (0.47 to 2.21) 4.63 (1.68 to 12.75)
*OR adjusted for maternal age, education level, folic acid use and periconceptional alcohol consumption.
BMI, body mass index; CHA, congenital heart anomalies.
Table 4 Interaction (adjusted synergy factors and 95% CIs) for
maternal smoking and high BMI combined for different cardiac
subgroups relative to non-cardiac chromosomal controls
Cardiac subgroups Interaction (SF) (95% CI)* p Value
All CHA (n¼797) 2.62 (1.12 to 6.17) 0.027
Septal defects (n¼349) 2.75 (1.07 to 7.08) 0.036
Conotruncal defects (n¼115) 4.28 (1.26 to 14.51) 0.020
Outflow tract anomalies (n¼265) 2.94 (1.12 to 7.71) 0.028
Left ventricular outflow tract
obstructive anomalies (n¼139)
3.59 (1.19 to 10.87) 0.024
Right ventricular outflow tract
obstructive anomalies (n¼126)
2.87 (0.94 to 8.79) 0.065
*Adjusted for maternal age, education level, folic acid use and periconceptional alcohol
consumption.
BMI, body mass index; CHA, congenital heart anomalies; SF, synergy factors.
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both positive and negative associations.3 However, these studies
did not determine whether there was interaction between
smoking and BMI but merely adjusted for these factors. By
conﬁrming associations identiﬁed previously between smoking
and BMI for different speciﬁc cardiac subgroups, we show the
validity of our data. We conﬁrmed previously described associ-
ations with high BMI and increased risk for RVOTO defects,6 as
well as previously described associations between periconcep-
tional smoking and atrial septal defects and pulmonary valve
stenosis.23 24
The interaction found between high BMI and smoking for
speciﬁc cardiac subgroups strengthens the hypothesis that heart
defects are complex in origin and that a pathogenic mechanism
could be shared by both risk factors. In a recent study Hobbs
et al suggest that genetic polymorphisms in genes encoding
enzymes in folate-dependent pathways could act as such
a shared mechanism.25 Studies on the role of different genetic
polymorphisms that hypothetically interact with maternal
lifestyle factors are still inconclusive, but they do suggest that
these polymorphisms play only a minor role.26
Proposed mechanisms on maternal overweight and the
increased risk for CHA in offspring are hyperglycaemia-induced
oxidative stress because of insulin resistance27 28 and fetal
hypoxia.29 The latter is also mentioned in literature as the
underlying mechanism that causes CHA associated with intra-
uterine tobacco smoke exposure.30 Although several suggestions
have been made, the exact mechanisms underlying the terato-
genicity associated with maternal overweight and/or tobacco
smoke remain unclear. Interestingly, obesity and smoking affect
plasma cholesterol levels, often resulting in dyslipidaemia with
increased low density lipoprotein levels and decreased high
density lipoprotein levels.11 12 Cholesterol is essential for fetal
cardiac development regulated by the sonic hedgehog tran-
scription pathway.31 In the ﬁrst trimester of pregnancy, mater-
nally-derived cholesterol is an important source of cholesterol for
the fetus, as animal studies have indicated.32 The heart defects
in our study that were associated with these lifestyle factors (eg,
RVOTO, septal defects) have been previously described in rela-
tion to errors in the cholesterol metabolism and downstream
pathways.33e35 We therefore hypothesise maternal dyslipi-
daemia as a possible shared mechanism to explain the interac-
tion between maternal smoking and overweight.
In conclusion, our study is the ﬁrst to suggest that there is
strong interaction between maternal smoking and high BMI in
the risk for CHA in offspring. The results indicate that maternal
smoking and overweight may both be involved in the same
pathway that causes congenital heart defects. It is important to
replicate our ﬁndings in larger datasets with non-malformed
controls and enough statistical power to analyse the interaction
in smaller CHA subgroups and more BMI subgroups. We
furthermore suggest that future case-control studies should
include interaction calculations when exploring risk factors for
congenital (heart) anomalies.
Our results add to the strong existing evidence that both
smoking and overweight are related to adverse pregnancy
outcomes such as intrauterine fetal death, small for gestational
age and preterm birth. We recommend that smoking cessation
should be strongly emphasised in preconception care, especially
in overweight women. Further research into the effect of
maternal cholesterol disturbances and maternal-fetal cholesterol
transport defects in the aetiology of congenital heart defects is
particularly important, since women of childbearing age are
increasingly suffering from cholesterol-related diseases and
conditions such as obesity and diabetes.
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